Loading...
Loading...
India's empagliflozin imports from CANADA total $15.1K across 33 shipments from 7 foreign suppliers. APOTEX INC leads with $3.8K in import value; the top 5 suppliers together control 89.6% of this origin. Leading Indian buyers include APOTEX RESEARCH PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for empagliflozin โ a diversified sourcing base with multiple active suppliers from CANADA.

APOTEX INC is the leading Empagliflozin supplier from CANADA to India, with import value of $3.8K across 3 shipments. The top 5 suppliers โ APOTEX INC, NewLife Medicals (USA). Inc., GLOBYZ PHARMA, JAMP PHARMA CORPORATION, TARO PHARMACEUTICALS INC. โ collectively account for 89.6% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | APOTEX INC | $3.8K | 3 | 25.0% |
| 2 | NewLife Medicals (USA). Inc. | $3.7K | 2 | 24.2% |
| 3 | GLOBYZ PHARMA | $2.6K | 9 | 17.4% |
| 4 | JAMP PHARMA CORPORATION | $2.0K | 10 | 13.5% |
| 5 | TARO PHARMACEUTICALS INC. | $1.4K | 6 | 9.5% |
| 6 | AURO PHARMA INC., CANADA | $923 | 2 | 6.1% |
| 7 | SANDOZ CANADA INC. | $650 | 1 | 4.3% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | APOTEX RESEARCH PRIVATE LIMITED | $3.8K | 3 | 25.0% |
| 2 | ALEMBIC PHARMACEUTICALS LIMITED | $3.7K | 2 | 24.2% |
| 3 | UNISON PHARMACEUTICALS PRIVATE LIMITED |
CANADA โ India trade corridor intelligence
The Canada to India pharmaceutical trade corridor is characterized by:
1. Port Congestion: Major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra have experienced congestion, leading to potential delays in shipments.
2. Freight Rates: Air freight rates from Canada to India have seen fluctuations due to global supply chain dynamics, impacting the cost-effectiveness of air shipments.
3. Currency Exchange: The Indian Rupee (INR) has experienced volatility against the Canadian Dollar, affecting the landed cost of imports.
These factors necessitate strategic planning and risk management for stakeholders involved in the trade corridor.
India's self-reliance initiatives, such as the Atmanirbhar Bharat Abhiyan, aim to reduce dependency on imports:
1. PLI Scheme Impact: The Production Linked Incentive (PLI) scheme encourages domestic manufacturing of pharmaceuticals, potentially reducing the need for imports like Empagliflozin formulations.
2. Import Substitution Policies: Policies are being developed to promote domestic production and reduce reliance on foreign suppliers.
While these initiatives may impact future import volumes, the immediate demand for Empagliflozin formulations continues to support imports from countries like Canada.
| $2.0K |
| 9 |
| 13.3% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $1.4K | 6 | 9.5% |
| 5 | ZYDUS LIFESCIENCES LIMITED | $1.1K | 2 | 7.2% |
| 6 | FINOSO PHARMA PRIVATE LIMITED | $1.1K | 6 | 7.0% |
| 7 | AUROBINDO PHARMA LTD | $923 | 2 | 6.1% |
| 8 | VEEDA CLINICAL RESEARCH LIMITED | $650 | 1 | 4.3% |
| 9 | CLIANTHA RESEARCH LIMITED | $487 | 1 | 3.2% |
| 10 | AXIS CLINICALS LIMITED | $31 | 1 | 0.2% |
India and Canada share a growing trade relationship, with several initiatives underway:
1. Free Trade Agreement (FTA) Negotiations: Discussions are ongoing to establish an FTA, which could streamline trade processes and reduce tariffs.
2. Mutual GMP Recognition: Efforts are being made to recognize each other's Good Manufacturing Practices (GMP), facilitating smoother pharmaceutical trade.
3. Pharma Trade Facilitation: Joint initiatives aim to enhance the efficiency and transparency of pharmaceutical trade between the two nations.
These developments are expected to strengthen bilateral trade and benefit stakeholders in both countries.
The estimated landed cost for importing finished Empagliflozin formulations from Canada to India includes:
1. FOB from Canada: The cost of the product as agreed upon between the buyer and seller.
2. Freight and Insurance: Costs associated with shipping the product from Canada to India, including insurance coverage.
3. Basic Customs Duty (BCD): 10% of the CIF value.
4. Social Welfare Surcharge (SWS): 1% of the CIF value.
5. Integrated Goods and Services Tax (IGST): 12% on the total of CIF value, BCD, and SWS.
6. Port Handling and CHA
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Empagliflozin into India, the following regulatory approvals are mandatory:
1. Import License: An Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is required. Additionally, an import license from the Central Drugs Standard Control Organization (CDSCO) is necessary for each consignment.
2. CDSCO Registration: The product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product type. This registration ensures the product meets India's safety, efficacy, and quality standards.
3. Drug Controller General of India (DCGI) Approval: The DCGI evaluates the product's clinical data and approves its use in India.
4. No Objection Certificate (NOC): If the product is already marketed in another country, an NOC from the regulatory authority of that country may be required.
The registration process typically takes 6 to 12 months, depending on the product's complexity and the completeness of the submitted documentation.
Imported pharmaceutical formulations containing Empagliflozin must undergo stringent quality control measures:
1. CDSCO-Approved Laboratory Testing: Each batch must be tested in a laboratory approved by CDSCO to ensure compliance with Indian Pharmacopoeia standards.
2. Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the product's composition, potency, and purity, is required for each batch.
3. Stability Data: Stability studies must be conducted under ICH Zone IV conditions to demonstrate the product's shelf-life in India's climate.
4. Port Inspection: Upon arrival, customs drug inspectors may perform random sampling and testing to verify compliance with Indian standards.
Failure to meet these requirements can result in delays, rejections, or destruction of the consignment.
Between 2024 and 2026, India has implemented several regulatory updates affecting pharmaceutical imports:
1. Mandatory Import Registration and License: As of April 2025, the CDSCO has mandated that all imported drugs, including finished formulations, must obtain import registration and licenses as per the Drugs and Cosmetics Act and Rules.
2. Pharmaceuticals PLI Scheme Impact: The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may influence the import of certain pharmaceutical products, including Empagliflozin formulations.
3. Bilateral Agreements with Canada: Ongoing discussions aim to streamline regulatory processes and enhance trade relations between India and Canada, potentially affecting pharmaceutical imports.
These changes aim to enhance drug safety, promote domestic manufacturing, and strengthen bilateral trade ties.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Empagliflozin formulations to meet the growing demand for diabetes management:
1. Patented Formulations: Certain patented Empagliflozin formulations not available domestically are imported to provide patients with the latest treatment options.
2. Specific Dosage Forms: Specialized dosage forms, such as combination tablets, are imported to cater to diverse patient needs.
3. Domestic Capacity vs. Import Dependency: While India has a robust pharmaceutical manufacturing sector, the complexity and cost of producing certain formulations lead to reliance on imports.
4. Market Size: The Indian market for Empagliflozin formulations is substantial, with imports supplementing domestic production to meet patient needs.
This import strategy ensures access to a comprehensive range of treatment options for diabetes patients in India.
The import of finished pharmaceutical formulations containing Empagliflozin is subject to the following duties and taxes:
1. Basic Customs Duty (BCD): A standard rate of 10% is applied to the CIF (Cost, Insurance, and Freight) value.
2. Social Welfare Surcharge (SWS): Calculated at 10% of the BCD, amounting to 1% of the CIF value.
3. Integrated Goods and Services Tax (IGST): Levied at 12% on the total of CIF value, BCD, and SWS.
4. Total Landed Duty: Approximately 23.536% of the CIF value, considering abatement factors.
These duties are subject to change based on government notifications and trade agreements.
India sources finished Empagliflozin formulations from Canada due to several competitive advantages:
1. Patents and Specialized Dosage Forms: Canadian manufacturers offer patented formulations and specialized dosage forms not available domestically.
2. Quality Assurance: Canada's stringent regulatory standards ensure high-quality products, instilling confidence among Indian importers.
3. Regulatory Compliance: Canadian pharmaceutical companies adhere to international standards, facilitating smoother import processes.
While other countries like China, Germany, and the US also supply Empagliflozin formulations, Canada's unique combination of quality, innovation, and regulatory compliance makes it a preferred source for India.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Empagliflozin suppliers from CANADA to India include APOTEX INC, NewLife Medicals (USA). Inc., GLOBYZ PHARMA. The leading supplier is APOTEX INC with import value of $3.8K USD across 3 shipments. India imported Empagliflozin worth $15.1K USD from CANADA in total across 33 shipments.
India imported Empagliflozin worth $15.1K USD from CANADA across 33 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Empagliflozin sourced from CANADA include APOTEX RESEARCH PRIVATE LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, UNISON PHARMACEUTICALS PRIVATE LIMITED. The largest buyer is APOTEX RESEARCH PRIVATE LIMITED with $3.8K in imports across 3 shipments.
The total value of Empagliflozin imports from CANADA to India is $15.1K USD, across 33 shipments and 7 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
33 Verified Shipments
7 suppliers, 10 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists